Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection

被引:62
作者
Tsubota, A
Hirose, Y
Izumi, N
Kumada, H
机构
[1] Toranomon Gen Hosp, Dept Gastroenterol, Minato Ku, Tokyo 1058470, Japan
[2] Okinaka Mem Inst Med Res, Minato Ku, Tokyo, Japan
[3] Yamanashi Prefectural Cent Hosp, Kofu, Yamanashi, Japan
[4] Musashino Red Cross Hosp, Div Gastroenterol & Hepatol, Musashino, Tokyo, Japan
关键词
chronic hepatitis C; genotype; 1b; high viral load; interferon alpha 2b; pharmacokinetics; ribavirin;
D O I
10.1046/j.1365-2125.2003.01780.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The aim of this study was to clarify the pharmacokinetics of ribavirin and interferon-alpha (IFN-alpha) 2b when administered in combination for 24 weeks and effects of pharmacokinetics of both on treatment outcome in chronic hepatitis C with genotype 1b and high viral load. Methods In this multicentre open study, 27 patients received 2-week daily induction therapy followed by 22-week, three-times-a-week maintenance therapy of intramuscular IFN-alpha 2b at a dose of 6 million units and oral ribavirin at 400 mg twice daily for 24 weeks, and followed up for 24 weeks post-treatment. Single- and multiple-dose pharmacokinetic studies were assessed by serial measurements of serum concentrations of both compounds at weeks 1 and 24. Results Five patients attained sustained virological response. Serum ribavirin concentrations asymptoted after 4-8 weeks of treatment in all patients. The steady-state concentration correlated significantly with serum ribavirin clearance after multiple dosing (r = -0.875; 95% CI -0.932, -0.721; P < 0.001). Serum concentrations at weeks 4 and 8, C-max and AUC(0,12 h) after multiple dosing and AUC(0,28 weeks) of ribavirin were significantly higher in sustained virological responders than in virological responders or nonresponders (P < 0.05, each). Increased C-max and accumulation index of AUC(0,12 h) (median 10.5; 95% CI 6.4, 12.4), and prolonged washout half-life after multiple dosing reflected accumulation and slow clearance of ribavirin from the tissue compartments. Conclusions Continuous exposure and accumulation of ribavirin may be necessary for sustained virological response to combination therapy in chronic hepatitis C with genotype 1b and high viral load.
引用
收藏
页码:360 / 367
页数:8
相关论文
共 23 条
[1]   A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta [J].
Asahina, Y ;
Izumi, N ;
Uchihara, M ;
Noguchi, O ;
Tsuchiya, K ;
Hamano, K ;
Kanazawa, N ;
Itakura, J ;
Miyake, S ;
Sakai, T .
HEPATOLOGY, 2001, 34 (02) :377-384
[2]  
CATLIN DH, 1980, RIBAVIRIN BROAD SPEC, P83
[3]   Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C [J].
Cramp, ME ;
Rossol, S ;
Chokshi, S ;
Carucci, P ;
Williams, R ;
Naoumov, NV .
GASTROENTEROLOGY, 2000, 118 (02) :346-355
[4]   Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499
[5]   RIBAVIRIN AS THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DIBISCEGLIE, AM ;
CONJEEVARAM, HS ;
FRIED, MW ;
SALLIE, R ;
PARK, Y ;
YURDAYDIN, C ;
SWAIN, M ;
KLEINER, DE ;
MAHANEY, K ;
HOOFNAGLE, JH ;
WRIGHT, D .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (12) :897-&
[6]   PLASMA DISAPPEARANCE, URINE EXCRETION, AND TISSUE DISTRIBUTION OF RIBAVIRIN IN RATS AND RHESUS-MONKEYS [J].
FERRARA, EA ;
OISHI, JS ;
WANNEMACHER, RW ;
STEPHEN, EL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 19 (06) :1042-1049
[7]  
Gibaldi M., 1982, PHARMACOKINETICS, P409
[8]   A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C [J].
Glue, P ;
Rouzier-Panis, R ;
Raffanel, C ;
Sabo, R ;
Gupta, SK ;
Salfi, M ;
Jacobs, S ;
Clement, RP .
HEPATOLOGY, 2000, 32 (03) :647-653
[9]   Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C [J].
Jen, JF ;
Glue, P ;
Gupta, S ;
Zambas, D ;
Hajian, G .
THERAPEUTIC DRUG MONITORING, 2000, 22 (05) :555-565
[10]   Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions [J].
Khakoo, S ;
Glue, P ;
Grellier, L ;
Wells, B ;
Bell, A ;
Dash, C ;
Murray-Lyon, I ;
Lypnyj, D ;
Flannery, B ;
Walters, K ;
Dusheiko, GM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (06) :563-570